Exclusive Summary

• - Global patents expired around 2012 with broad generic entry; no blocking IP remains, enabling rapid multi-country launch.
• - 4mg/5mg chewables target once-daily pediatric use (ages 2–14), addressing ~262M asthma and 400–500M rhinitis patients with high child comorbidity.
• - Guideline-aligned as alternative/add-on in children (GINA/ARIA) and for EIB; FDA 2020 boxed warning requires restricted use in allergic rhinitis and strict labeling/PV.
• - US-FDA GMP and US registration support reliance pathways, compliant labeling, and tender readiness across regions.
• - Typically 80–95% cheaper than the originator, enabling broad uptake in public procurement and retail Rx channels.